A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
Clinical trial NCT01748773 · COMPLETED
Trial details
- NCT number
- NCT01748773
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-29
- Primary completion
- 2015-08-21
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.